Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
August 20, 2025 at 7:51 PM
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
Heterogeneity in the expression [RNA] of GPRC5D between patients with multiple myeloma - @Phhersh et al. #ASCO25 Abst 7511 meetings.asco.org/abstracts-pr... #mmsm #PrecisionMedicine #cagenome #caxtx n=290 CD138 purified
May 23, 2025 at 3:51 PM
Heterogeneity in the expression [RNA] of GPRC5D between patients with multiple myeloma - @Phhersh et al. #ASCO25 Abst 7511 meetings.asco.org/abstracts-pr... #mmsm #PrecisionMedicine #cagenome #caxtx n=290 CD138 purified
First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results - van de Donk et al. #ASCO25 Abst 7505
meetings.asco.org/abstracts-pr... #mmsm #caxtx
meetings.asco.org/abstracts-pr... #mmsm #caxtx
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
May 23, 2025 at 3:14 PM
First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results - van de Donk et al. #ASCO25 Abst 7505
meetings.asco.org/abstracts-pr... #mmsm #caxtx
meetings.asco.org/abstracts-pr... #mmsm #caxtx
Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results - Lichtman et al. #ASCO25 Abst 7514
meetings.asco.org/abstracts-pr... #NCT05862012 #mmsm #caxtx
meetings.asco.org/abstracts-pr... #NCT05862012 #mmsm #caxtx
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
May 23, 2025 at 2:39 PM
Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results - Lichtman et al. #ASCO25 Abst 7514
meetings.asco.org/abstracts-pr... #NCT05862012 #mmsm #caxtx
meetings.asco.org/abstracts-pr... #NCT05862012 #mmsm #caxtx
Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study - @AlkassisSamer et al. #ASCO25 Abst 1041
meetings.asco.org/abstracts-pr... @TempusAI #bcsm #caxtx
meetings.asco.org/abstracts-pr... @TempusAI #bcsm #caxtx
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
May 23, 2025 at 1:13 PM
Transcriptomic biomarkers of therapeutic response to antibody-drug conjugates in metastatic breast cancer: A comprehensive multi-center study - @AlkassisSamer et al. #ASCO25 Abst 1041
meetings.asco.org/abstracts-pr... @TempusAI #bcsm #caxtx
meetings.asco.org/abstracts-pr... @TempusAI #bcsm #caxtx
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
May 18, 2025 at 10:57 PM
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
May 14, 2025 at 1:05 PM
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
May 2, 2025 at 4:52 PM
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx
March 22, 2025 at 2:07 PM
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
March 21, 2025 at 5:07 PM
Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm
Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark RCTs in Relapsed/Refractory Multiple Myeloma [Sep 2019] @AjaiChari et al. CLML ow.ly/L23c30qmAT2 #mmsm #ClinicalTrials #caxtx
March 3, 2025 at 3:10 PM
Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark RCTs in Relapsed/Refractory Multiple Myeloma [Sep 2019] @AjaiChari et al. CLML ow.ly/L23c30qmAT2 #mmsm #ClinicalTrials #caxtx
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis [Oct 10, 2023] @GemmaKReynolds et al. @benwteh @BloodAdvances ashpublications.org/bloodadvance... #IDonc #mmsm #caxtx
March 3, 2025 at 11:17 AM
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis [Oct 10, 2023] @GemmaKReynolds et al. @benwteh @BloodAdvances ashpublications.org/bloodadvance... #IDonc #mmsm #caxtx
Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients [Sep 6, 2023] @benwteh et al. @TheLancetInfDis doi.org/10.1016/S147... #IDonc #leusm #lymsm #mmsm #mpnsm #caxtx
Redirecting
doi.org
March 3, 2025 at 11:16 AM
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx
March 3, 2025 at 11:13 AM
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx
February 14, 2025 at 1:37 PM
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx
January 14, 2025 at 9:57 PM
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx
December 4, 2024 at 1:46 PM
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx
November 25, 2024 at 11:32 PM
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx
Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients [Sep 6, 2023] @benwteh et al. @TheLancetInfDis doi.org/10.1016/S147... #IDonc #leusm #lymsm #mmsm #mpnsm #caxtx
Redirecting
doi.org
November 18, 2024 at 7:05 PM